Abstract

It has been suggested that PAF-acether may be an important mediator in asthma and a PAF antagonist may therefore have a potentially important role. PAF-acether has been shown to induce a dual inflammatory reponse in the skin of man and we investigated the effect of BN 52063, a PAF antagonist, on this response. At a dose of 80mg, BN 52063 orally inhibited the inflammatory response to a sub-cutaneous injection of PAF-acether 400ng. A late cutaneous response was not observed in any of the subjects. BN 52063 was also demonstrated to be well tolerated at doses of 20, 40, 80 and 120mg with no significant side effects.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call